EU Approves BMS’ Orencia for Methotrexate-naive RA Patients

European Commission expanded approved indications for Bristol-Myers Squibb’s biologic Orencia, thereby allowing its use in patients with highly active and progressive rheumatoid arthritis that have not previously been treated with methotrexate. In the past the European regulator approved Orencia in combination with methotrexate in 2010 for adults who have moderate to severe active RA that

Continue Reading